Abstract Search

ey0018.6-16 | Longterm Effects of Hormonal Treatments in Gender Dysphoria | ESPEYB18

6.16. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study

A Weill , P Nguyen , M Labidi , B Cadier , T Passeri , L Duranteau , AL Bernat , I Yoldjian , S Fontanel , S Froelich , J Coste

BMJ. 2021 Feb 3;372:n37. doi: 10.1136/bmj.n37. PMID: 33536184This observational cohort study used data from the French administrative healthcare database during 20072015 to assess the risk of meningioma development related to treatment with cyproterone acetate. The cohort comprised 253,777 participants, of whom 54% had high exposure to cyproterone acetate, and 45% had low exposure.<p cla...

0 shares

ey0018.4-6 | Growth Hormone Therapy: Safety | ESPEYB18

4.6. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study

L Savendahl , R Cooke , A Tidblad , D Beckers , G Butler , S Cianfarani , P Clayton , J Coste , ACS Hokken-Koelega , W Kiess , CE Kuehni , K Albertsson-Wikland , A Deodati , E Ecosse , R Gausche , C Giacomozzi , D Konrad , F Landier , R Pfaeffle , G Sommer , M Thomas , S Tollerfield , GRJ Zandwijken , JC Carel , AJ Swerdlow

Lancet Diabetes Endocrinol. 2020;8(8):683692. doi: 10.1016/S2213-8587(20)30163-7. PMID: 32707116SAGhE is a large independent European consortium including eight different countries (Belgium, France, Germany, Italy, The Netherlands, Sweden, Switzerland, and the UK) which was set up to evaluate the long-term safety of rhGH in a large cohort (>24 000) of young adult patients t...

1 shares

ESPE Yearbook of Paediatric Endocrinology

6.16. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study

4.6. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study

BiosciAbstracts